Hologic

559 articles with Hologic

• Hologic to Announce Financial Results for the Fourth Quarter of Fiscal 2020 on Wednesday, November 4, 2020

  10/7/2020

  Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the fourth quarter of fiscal 2020 on Wednesday, November 4, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time. Interested participants may listen to the call by dialing 888-204-4368 (in the United States and Canada) or +1 323-994-

• FDA Amends Emergency Use Authorization for Hologic’s Aptima SARS-CoV-2 Assay to Include COVID-19 Testing of Asymptomatic Individuals, Symptomatic Sample Pooling

  10/6/2020

  Hologic, Inc. (Nasdaq: HOLX) announced today that its Aptima® SARS-CoV-2 assay, which initially received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) in May, is now authorized for testing of individuals without symptoms or other reasons to suspect COVID-19 infection.

• Hologic Granted FDA Emergency Use Authorization for Asymptomatic COVID-19 Testing with Panther Fusion SARS-CoV-2 Assay

  9/28/2020

  Hologic, Inc. (Nasdaq: HOLX) announced today that its Panther Fusion® SARS-CoV-2 assay has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for testing of individuals without symptoms or other reasons to suspect COVID-19 infection. Hologic

• Hologic Announces Pricing of Offering of $950 Million of 3.250% Senior Notes Due 2029

  9/14/2020

  Hologic, Inc. (Nasdaq: HOLX) announced today that it has priced its previously announced private offering of $950 million aggregate principal amount of 3.250% senior notes due 2029 at an issue price of $1,000 per $1,000.

• Hologic Announces Offering of $950 Million of Senior Notes Due 2029

  9/14/2020

  Hologic, Inc. (Nasdaq: HOLX) announced today that it has launched, subject to market and other conditions, a private offering of $950 million aggregate principal amount of senior notes due 2029. Hologic intends to use the proceeds of the offering and available cash to refinance its existing 4.375% senior unsecu

• Hologic to Webcast Presentations at Upcoming Investor Conferences - Sep 04, 2020

  9/4/2020

  Hologic, Inc. announced that the Company will present at these upcoming virtual investor conferences

• Hologic to Acquire Acessa Health, Innovator in Minimally Invasive Solutions for Treatment of Fibroids

  8/25/2020

  Hologic, Inc. (Nasdaq: HOLX), a global leader in women's health, announced today that it has acquired Acessa Health Inc., a privately-held innovator in minimally invasive treatment for fibroids, for approximately $80 million in cash plus contingent payments based on future revenue growth.

• Hologic Announces 'Back to Screening' Campaign Encouraging Women to Prioritize Scheduling Annual Mammograms

  8/20/2020

  Campaign offers a chance to attend a private, virtual performance by GRAMMY®Award-winning artist and breast cancer survivor Sheryl Crow   [20-August-2020]   MARLBOROUGH, Mass. , Aug. 20, 2020 /PRNewswire/ -- WHAT:  At the start of the COVID-19 pandemic, many health officials, professional societies and patient a

• Hologic Launches Validated Pooling Protocol for COVID-19 Testing

  8/11/2020

  In Time of Extraordinary Need, New Protocol Expected to Help Laboratories Deliver Greater Quantities of Highly Accurate Molecular Test Results and Reduce Turnaround Times

• New Cervical Cancer Screening Guidelines from the American Cancer Society Risk Reversing Decades of Progress Made Against Cervical Cancer

  7/31/2020

  If followed, guidelines would reduce ability of women and their doctors to choose widely adopted Pap-based testing strategies that have proven highly effective

• Hologic Announces Financial Results for Third Quarter of Fiscal 2020

  7/29/2020

  Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal third quarter ended June 27, 2020.

• Hologic Launches its First Cart-Based Ultrasound System, SuperSonic™ MACH 40

  7/8/2020

  Hologic, Inc. (Nasdaq: HOLX) announced today the U.S. launch of the SuperSonic™ MACH 40 ultrasound system, expanding the Company’s suite of ultrasound technologies with its first premium, cart-based system.

• Hologic to Announce Financial Results for the Third Quarter of Fiscal 2020 on Wednesday, July 29, 2020

  7/2/2020

  Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the third quarter of fiscal 2020 on Wednesday, July 29, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time. Interested participants may listen to the call by dialing 800-263-0877 (in the United States and Canada) or +1 323-794-2094

• Hologic to Webcast Presentations at Upcoming Virtual Investor Conferences in June 2020

  6/1/2020

  Hologic, Inc. announced that the Company will present at these upcoming virtual investor conferences

• Hologic Granted FDA Emergency Use Authorization for Its Second Molecular Test for COVID-19

  5/15/2020

  Significant Test Manufacturing Capacity, Large Installed Base of Automated Instruments Yield Testing Breakthrough --

• Hologic to Webcast Presentations at Upcoming Investor Conferences in May 2020

  5/6/2020

  Hologic, Inc. announced that the Company will present at these upcoming virtual investor conferences

• Hologic to Introduce Its Second High-Throughput Molecular Assay for the Novel Coronavirus (SARS-CoV-2)

  4/29/2020

  Hologic, Inc. (Nasdaq: HOLX) announced today that it plans to launch a new Aptima® molecular assay to detect the SARS-CoV-2 virus that will run on its market-leading Panther® system.

• Hologic Announces Financial Results for Second Quarter of Fiscal 2020

  4/29/2020

  Hologic, Inc. (Nasdaq: HOLX) announced today the Company’s financial results for the fiscal second quarter ended March 28, 2020.

• Hologic Announces Preliminary Revenue Results for Second Quarter of Fiscal 2020, Withdraws 2020 Financial Guidance due to COVID-19 Pandemic

  4/7/2020

  Hologic, Inc. announced preliminary revenue results for its second fiscal quarter ended March 28, 2020, and withdrew its 2020 financial guidance due to the uncertain economic impact of the COVID-19 pandemic.

• Hologic to Announce Financial Results for the Second Quarter of Fiscal 2020 on Wednesday, April 29, 2020

  4/7/2020

  Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the second quarter of fiscal 2020 on Wednesday, April 29, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time. Interested participants may listen to the call by dialing 888-204-4368 (in the United States and Canada) or +1 323-994-2